PDF(Pubmed)
Abstract：
UNASSIGNED: Although Coronavirus disease 2019 (COVID-19) vaccination is critical to control its spread, vaccine hesitancy varies significantly among the United States population; moreover, some vaccine recipients experienced various adverse effects. We aim to assess the impact of COVID-19 vaccine hesitancy in a university-affiliated community, the factors affecting participants\' decisions, and their adverse effects.
UNASSIGNED: A pre-vaccination online Institutional Review Board IRB-approved survey was emailed in Nov/Dec 2020, 2 months before the implementation of state-policy protocols for COVID-19 vaccination. A post-vaccination survey was emailed in May/June 2021, two months after protocol execution. A third follow-up survey was sent in Nov/Dec 2021, and a fourth was sent in June/July 2022. The study population included three groups of adult participants: university students, faculty, and staff-(MS), university health system patients-(MP), and Cancer Center patients-(MCP). The study was designed as a longitudinal cohort study. Statistical analyses were performed using SPSS.
UNASSIGNED: With a combined response rate of 26% (40,578/157,292) among the four surveys, 15,361 participants completed the first survey (MS = 4,983, MP = 9,551, and MCP = 827). 2/3 of participants (63.5%) were willing to get vaccinated, with a significant difference in acceptance among groups, MS:56.6%, MP:66.2%, and MCP:71.6% (p < 0.05). Vaccine acceptance rates reached 89% in the second survey after the vaccine\'s approval, with a lower acceptance rate of MS:84.6% than with MP:90.74% and MCP:92.47% participants (p < 0.05). Safety and effectiveness concerns were the main factors affecting participants\' decisions in all the first three surveys; however, participants reported these concerns decreased between pre-vaccination, post-vaccination, and follow-up surveys with 87%, 56%, and 46%, respectively(p < 0.05). More than two-thirds of the participants (70%) reported having either minor/moderate symptoms (61.6%) or major symptoms (8.6%) after getting some of the vaccine doses (p < 0.05).
UNASSIGNED: The hesitance of COVID-19 vaccination was associated with concerns regarding its safety and efficacy. Vaccine acceptance rose higher than expected after protocol execution, likely due to continuous education, whereas safety and efficacy remain factors hindering vaccine acceptance. Continuous education focusing on safety and efficacy of the vaccine can reduce vaccine hesitancy and raise the rates of vaccination.
UNASSIGNED: A pre-vaccination online Institutional Review Board IRB-approved survey was emailed in Nov/Dec 2020, 2 months before the implementation of state-policy protocols for COVID-19 vaccination. A post-vaccination survey was emailed in May/June 2021, two months after protocol execution. A third follow-up survey was sent in Nov/Dec 2021, and a fourth was sent in June/July 2022. The study population included three groups of adult participants: university students, faculty, and staff-(MS), university health system patients-(MP), and Cancer Center patients-(MCP). The study was designed as a longitudinal cohort study. Statistical analyses were performed using SPSS.
UNASSIGNED: With a combined response rate of 26% (40,578/157,292) among the four surveys, 15,361 participants completed the first survey (MS = 4,983, MP = 9,551, and MCP = 827). 2/3 of participants (63.5%) were willing to get vaccinated, with a significant difference in acceptance among groups, MS:56.6%, MP:66.2%, and MCP:71.6% (p < 0.05). Vaccine acceptance rates reached 89% in the second survey after the vaccine\'s approval, with a lower acceptance rate of MS:84.6% than with MP:90.74% and MCP:92.47% participants (p < 0.05). Safety and effectiveness concerns were the main factors affecting participants\' decisions in all the first three surveys; however, participants reported these concerns decreased between pre-vaccination, post-vaccination, and follow-up surveys with 87%, 56%, and 46%, respectively(p < 0.05). More than two-thirds of the participants (70%) reported having either minor/moderate symptoms (61.6%) or major symptoms (8.6%) after getting some of the vaccine doses (p < 0.05).
UNASSIGNED: The hesitance of COVID-19 vaccination was associated with concerns regarding its safety and efficacy. Vaccine acceptance rose higher than expected after protocol execution, likely due to continuous education, whereas safety and efficacy remain factors hindering vaccine acceptance. Continuous education focusing on safety and efficacy of the vaccine can reduce vaccine hesitancy and raise the rates of vaccination.
摘要：
■尽管2019年冠状病毒病（COVID-19）疫苗接种对控制其传播至关重要，疫苗犹豫在美国人口中差异很大；此外，一些疫苗接种者经历了各种不良反应。我们的目标是评估COVID-19疫苗犹豫在一个大学附属社区的影响，影响参与者决策的因素，以及它们的不利影响。
一项接种前机构审查委员会批准的在线调查于2020年11月/12月通过电子邮件发送，距离实施COVID-19疫苗接种国家政策协议还有2个月。疫苗接种后调查于2021年5月/6月通过电子邮件发送，也就是协议执行两个月后。第三次跟踪调查于2021年11月/12月发送，第四次于2022年6月/7月发送。研究人群包括三组成年参与者：大学生，教员,和员工-(MS)，大学卫生系统患者-（MP），和癌症中心患者-（MCP）。该研究设计为纵向队列研究。使用SPSS进行统计分析。
■在四项调查中，综合反应率为26％（40,578/157,292），15,361名参与者完成了第一次调查（MS=4,983，MP=9,551，MCP=827）。2/3的参与者（63.5%）愿意接种疫苗，群体之间的接受度有显著差异，MS:56.6%,MP：66.2%，MCP:71.6%(p<0.05)。在疫苗批准后的第二次调查中，疫苗接受率达到89%，MS的接受率：84.6%低于MP：90.74%和MCP：92.47%（p<0.05）。在前三项调查中，安全性和有效性问题是影响参与者决策的主要因素；然而，参与者报告说，这些担忧在疫苗接种前之间有所减少，疫苗接种后，以及87%的后续调查，56%,46%,分别为(p<0.05)。超过三分之二的参与者（70％）报告说在获得一些疫苗剂量后有轻微/中度症状（61.6％）或主要症状（8.6％）（p<0.05）。
■COVID-19疫苗接种的犹豫与对其安全性和有效性的担忧有关。方案执行后，疫苗接受度高于预期，可能是由于持续的教育，而安全性和有效性仍然是阻碍疫苗接受的因素。以疫苗的安全性和有效性为重点的持续教育可以减少疫苗的犹豫，提高疫苗接种率。
一项接种前机构审查委员会批准的在线调查于2020年11月/12月通过电子邮件发送，距离实施COVID-19疫苗接种国家政策协议还有2个月。疫苗接种后调查于2021年5月/6月通过电子邮件发送，也就是协议执行两个月后。第三次跟踪调查于2021年11月/12月发送，第四次于2022年6月/7月发送。研究人群包括三组成年参与者：大学生，教员,和员工-(MS)，大学卫生系统患者-（MP），和癌症中心患者-（MCP）。该研究设计为纵向队列研究。使用SPSS进行统计分析。
■在四项调查中，综合反应率为26％（40,578/157,292），15,361名参与者完成了第一次调查（MS=4,983，MP=9,551，MCP=827）。2/3的参与者（63.5%）愿意接种疫苗，群体之间的接受度有显著差异，MS:56.6%,MP：66.2%，MCP:71.6%(p<0.05)。在疫苗批准后的第二次调查中，疫苗接受率达到89%，MS的接受率：84.6%低于MP：90.74%和MCP：92.47%（p<0.05）。在前三项调查中，安全性和有效性问题是影响参与者决策的主要因素；然而，参与者报告说，这些担忧在疫苗接种前之间有所减少，疫苗接种后，以及87%的后续调查，56%,46%,分别为(p<0.05)。超过三分之二的参与者（70％）报告说在获得一些疫苗剂量后有轻微/中度症状（61.6％）或主要症状（8.6％）（p<0.05）。
■COVID-19疫苗接种的犹豫与对其安全性和有效性的担忧有关。方案执行后，疫苗接受度高于预期，可能是由于持续的教育，而安全性和有效性仍然是阻碍疫苗接受的因素。以疫苗的安全性和有效性为重点的持续教育可以减少疫苗的犹豫，提高疫苗接种率。
